Tumor suppressor protein plays key role in suppressing infections

June 20, 2018

Researchers have found that a previously uncharacterized tumor-suppressor protein plays an important role in the functioning of the immune system. The study, which will be published in the June 22 issue of the Journal of Biological Chemistry, unites studies of immunology and cancer biology.

The gene encoding the protein Arl11 (part of the Ras GTPase family of proteins) is frequently turned off or mutated in cancer cells; conversely, when a functioning Arl11 gene is inserted into lung carcinoma cells, the cells die. These types of evidence have led scientists to categorize Arl11 as a tumor-suppressor protein. But it was almost completely unknown what Arl11's fundamental role was in healthy cells and healthy organisms.

"We really wanted to know how this protein works," said Amit Tuli, the investigator at the CSIR-Institute of Microbial Technology in India who oversaw the study.

Tuli's team began its investigation with the observation that the gene encoding Arl11 was turned on, or expressed, in immune cells called macrophages. Macrophages are white blood cells that destroy pathogens and other foreign substances by consuming them.

Performing experiments in cultured cells from mice and humans, the team found that Arl11 was crucial for macrophages to be able to detect and destroy pathogens. Arl11 was turned on in macrophages when they encountered bacteria (or components from bacterial cell membranes). Macrophages in which Arl11 expression was silenced did not engulf bacteria the way they were supposed to or release signaling molecules called cytokines that activate other immune cells. When macrophages were infected with Salmonella, those lacking Arl11 were unable to stop the bacteria from proliferating.

"This is the first study which provides the first clue to the cellular function of Arl11," Tuli said. "Our study reveals that Arl11 expression actually increases when macrophages encounter a pathogen... this increasing expression of Arl11 is very much required to control the functions of macrophages."

Arl11 appears to act by initiating a signaling cascade called the ERK/MAP kinase pathway, which is known to regulate the division of cells and is therefore implicated in cancer. Depending on whether the pathway is turned on briefly or for extended lengths of time, cells either proliferate or die. This connection probably underlies Arl11's connection to cancer, which Tuli's team is now exploring. The discovery also opens up new directions of research.

"Understanding how the immune system functions is crucial not only for immunotherapy against cancer, but it can also be important (for conditions involving) inflammation, which actually damages the normal tissues," Tuli said. "I think it's really relevant in the future to study Arl11 expression in such conditions, for example, autoimmune diseases or obesity."
The study was funded by the Wellcome Trust/DBT India Alliance and CSIR.

About the Journal of Biological Chemistry

JBC is a weekly peer-reviewed scientific journal that publishes research "motivated by biology, enabled by chemistry" across all areas of biochemistry and molecular biology. The read the latest research in JBC, visit http://www.jbc.org/.

About the American Society for Biochemistry and Molecular Biology

The ASBMB is a nonprofit scientific and educational organization with more than 12,000 members worldwide. Most members teach and conduct research at colleges and universities. Others conduct research in various government laboratories, at nonprofit research institutions and in industry. The Society's student members attend undergraduate or graduate institutions. For more information about ASBMB, visit http://www.asbmb.org.

American Society for Biochemistry and Molecular Biology

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.